Showing 1951-1960 of 5771 results for "".
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Prevent Blindness to Hold 16th Annual “Eyes on Capitol Hill” Advocacy Eventhttps://modernod.com/news/prevent-blindness-to-hold-16th-annual-eyes-on-capitol-hill-advocacy-event/2478850/Prevent Blindness will be holding its sixteenth annual “
- Palatin Technologies Announces Filing of International Patent Application for Lead Compound for Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-filing-of-international-patent-application-for-lead-compound-for-dry-eye-disease/2478853/Palatin Technologies announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides. Palatin recently reported positive results in its phase 2 study of PL9643
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- Bausch Health Announces Vyzulta is Now Approved in South Koreahttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-south-korea/2478847/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval from the Ministry of Food and Drug Safety in South Korea. Vyzulta is indicated for the reduction of IOP in patients w
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- Surface Ophthalmics Announces First Patient Dosed in Phase 2 Trial for SURF-200 for Acute Dry Eyehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-phase-2-trial-for-surf-200-for-acute-dry-eye/2478833/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye. In this dose-ranging study, SURF-200 will be studied in two different low concen
- Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 for Thyroid Eye Diseasehttps://modernod.com/news/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-for-thyroid-eye-disease/2478829/Immunovant announced a voluntary pause of dosing in its ongoing clinical trials of its investigational drug IMVT-1401 for the treatment of Thyroid Eye Disease (TED). The company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels